Ragu Ramanathan
Research Subjects
Ragu Ramanathan has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Walter Korfmacher
Drug Metabolism & Pharmacokinetics, Sanofi, Waltham, MA, USA
3 shared publicationsA David Rodrigues
Pfizer Global R&D, Medicine Design-ADME Sciences, Groton, CT, USA, 06340
2 shared publicationsAmanda J. King-Ahmad
Research & Development, Pharmacokinetics, Dynamics & Metabolism, Pfizer Inc., 445 Eastern Point Road, Groton, CT 06340, USA
1 shared publication- Amanda King-Ahmad
Pfizer Global R&D, Medicine Design-ADME Sciences, Groton, CT, USA, 06340
1 shared publication - Christopher Holliman
Pharmacokinetics, Dynamics & Metabolism, Research & Development, Pfizer Inc., 445 Eastern Point Road, Groton, CT 06340, USA
1 shared publication Christopher L Holliman
Research & Development, Pharmacokinetics, Dynamics & Metabolism, Pfizer Inc., 445 Eastern Point Road, Groton, CT 06340, USA
1 shared publication
Latest Publications
- 16 February 2023
- Published by Springer Nature in Archives of Toxicology
- Vol. 97 (4) , 947-961
Circulating microRNAs as promising testicular translatable safety biomarkers: current state and future perspectives
Drug-induced testicular injury (DITI) is one of the often-observed and challenging safety issues seen during drug development. Semen analysis and circulating hormones currently utilized have significant gaps in their ability to detect testicular damage accurately. In addition, no biomarkers enable a mechanistic understanding of the damage to the different regions of the testis, such as seminiferous tubules, Sertoli, and Leydig cells. MicroRNAs (miRNAs) are a class of non-coding RNAs that modulate gene expression post-transcriptionally and have been indicated to regulate a wide range of biological pathways. Circulating miRNAs can be measured in the body fluids due to tissue-specific cell injury/damage or toxicant exposure. Therefore, these circulating miRNAs have become attractive and promising non-invasive biomarkers for assessing drug-induced testicular injury, with several reports on their use as safety biomarkers for monitoring testicular damage in preclinical species. Leveraging emerging tools such as ‘organs-on-chips’ that can emulate the human organ’s physiological environment and function is starting to enable biomarker discovery, validation, and clinical translation for regulatory qualification and implementation in drug development.
- 16 February 2023
- Published by Springer Nature in Archives of Toxicology
- Vol. 97 (4) , 947-961
Circulating microRNAs as promising testicular translatable safety biomarkers: current state and future perspectives
Drug-induced testicular injury (DITI) is one of the often-observed and challenging safety issues seen during drug development. Semen analysis and circulating hormones currently utilized have significant gaps in their ability to detect testicular damage accurately. In addition, no biomarkers enable a mechanistic understanding of the damage to the different regions of the testis, such as seminiferous tubules, Sertoli, and Leydig cells. MicroRNAs (miRNAs) are a class of non-coding RNAs that modulate gene expression post-transcriptionally and have been indicated to regulate a wide range of biological pathways. Circulating miRNAs can be measured in the body fluids due to tissue-specific cell injury/damage or toxicant exposure. Therefore, these circulating miRNAs have become attractive and promising non-invasive biomarkers for assessing drug-induced testicular injury, with several reports on their use as safety biomarkers for monitoring testicular damage in preclinical species. Leveraging emerging tools such as ‘organs-on-chips’ that can emulate the human organ’s physiological environment and function is starting to enable biomarker discovery, validation, and clinical translation for regulatory qualification and implementation in drug development.
- 11 May 2018
- Published by Taylor & Francis in Bioanalysis
- Vol. 10 (9) , 691-701
A Fully Automated and Validated Human Plasma LC–MS/MS Assay for Endogenous OATP Biomarkers Coproporphyrin-I and Coproporphyrin-III
Aim: A validated LC–MS/MS assay for the quantitation of coproporphyrin-I and -III (CP-I, CP-III) in human plasma has been developed to understand the utility of both as possible endogenous biomarkers for organic anion-transporting polypeptides (OATP)-mediated drug–drug interactions (DDIs). Materials and Methods: Human plasma extracts were analyzed for CP-I and CP-III using a 6500+ mass spectrometer. Results: The assay was utilized for plasma samples from a clinical DDI study involving a new chemical entity that presented as an OATP inhibitor in vitro. A formal DDI study, with a probe drug (atorvastatin), was also included as part of the clinical study. Conclusion: Changes in CP-I plasma area under the plasma concentration versus time curve (AUC0–48 h) were observed, which were similar to the AUC ratio obtained with atorvastatin. These results support the idea that plasma CP-I may have utility in Phase I by supporting the rapid assessment of OATP inhibition risk.
- 11 May 2018
- Published by Taylor & Francis in Bioanalysis
- Vol. 10 (9) , 691-701
A Fully Automated and Validated Human Plasma LC–MS/MS Assay for Endogenous OATP Biomarkers Coproporphyrin-I and Coproporphyrin-III
Aim: A validated LC–MS/MS assay for the quantitation of coproporphyrin-I and -III (CP-I, CP-III) in human plasma has been developed to understand the utility of both as possible endogenous biomarkers for organic anion-transporting polypeptides (OATP)-mediated drug–drug interactions (DDIs). Materials and Methods: Human plasma extracts were analyzed for CP-I and CP-III using a 6500+ mass spectrometer. Results: The assay was utilized for plasma samples from a clinical DDI study involving a new chemical entity that presented as an OATP inhibitor in vitro. A formal DDI study, with a probe drug (atorvastatin), was also included as part of the clinical study. Conclusion: Changes in CP-I plasma area under the plasma concentration versus time curve (AUC0–48 h) were observed, which were similar to the AUC ratio obtained with atorvastatin. These results support the idea that plasma CP-I may have utility in Phase I by supporting the rapid assessment of OATP inhibition risk.
- 1 May 2018
- Published by Taylor & Francis in Bioanalysis
- Vol. 10 (9) , 609-613
Novel LC-MS assays impacting CYP and transporter drug-drug interaction evaluations
- 1 May 2018
- Published by Taylor & Francis in Bioanalysis
- Vol. 10 (9) , 609-613
Novel LC-MS assays impacting CYP and transporter drug-drug interaction evaluations
- 5 October 2017
- Published by Taylor & Francis in Bioanalysis
- Vol. 9 (22) , 1787-1806
A Highly Selective and Sensitive LC–MS/HRMS Assay for Quantifying Coproporphyrins as Organic Anion-Transporting Peptide Biomarkers
Aim: Coproporphyrin-I (CP-I) and coproporphyrin-III (CP-III) in plasma and urine have been proposed as biomarkers for assessing drug–drug interactions involving hepatic drug transporters such as organic anion-transporting peptides (OATP), 1B1 and 1B3. Materials & methods: Plasma and urine extracts were analyzed for CP-I/CP-III using a TripleTOF API6600 mass spectrometer. Results: Previously unreported, CP-I/CP-III doubly charged ions (m/z 328.14) were used as precursor ions to improve the assay sensitivity and selectivity over the singly charged precursor ions (m/z 655.28). Levels of CP-I and CP-III measured ranged 0.45–1.1 and 0.050–0.50 ng/ml in plasma and 5–35 and 1–35 ng/ml in urine, respectively. Conclusion: The described highly selective and sensitive CP-I/CP-III LC–HRMS assay offers options for earlier characterization and clinical safety projections for OATP1B1/3-mediated drug–drug interactions along with pharmacokinetic analyses of a new chemical entity as part of first-in-human clinical studies.
- 5 October 2017
- Published by Taylor & Francis in Bioanalysis
- Vol. 9 (22) , 1787-1806
A Highly Selective and Sensitive LC–MS/HRMS Assay for Quantifying Coproporphyrins as Organic Anion-Transporting Peptide Biomarkers
Aim: Coproporphyrin-I (CP-I) and coproporphyrin-III (CP-III) in plasma and urine have been proposed as biomarkers for assessing drug–drug interactions involving hepatic drug transporters such as organic anion-transporting peptides (OATP), 1B1 and 1B3. Materials & methods: Plasma and urine extracts were analyzed for CP-I/CP-III using a TripleTOF API6600 mass spectrometer. Results: Previously unreported, CP-I/CP-III doubly charged ions (m/z 328.14) were used as precursor ions to improve the assay sensitivity and selectivity over the singly charged precursor ions (m/z 655.28). Levels of CP-I and CP-III measured ranged 0.45–1.1 and 0.050–0.50 ng/ml in plasma and 5–35 and 1–35 ng/ml in urine, respectively. Conclusion: The described highly selective and sensitive CP-I/CP-III LC–HRMS assay offers options for earlier characterization and clinical safety projections for OATP1B1/3-mediated drug–drug interactions along with pharmacokinetic analyses of a new chemical entity as part of first-in-human clinical studies.
- 1 May 2013
- Published by Future Science Ltd in Bioanalysis
- Vol. 5 (10) , 1139-1140
Preface to the 2013 Special Focus Issue of Bioanalysis on high-resolution MS
- 1 May 2013
- Published by Future Science Ltd in Bioanalysis
- Vol. 5 (10) , 1139-1140
Preface to the 2013 Special Focus Issue of Bioanalysis on high-resolution MS
- 1 January 2011
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 39 (1) , 123-131
Plasma Stability-Dependent Circulation of Acyl Glucuronide Metabolites in Humans: How Circulating Metabolite Profiles of Muraglitazar and Peliglitazar Can Lead to Misleading Risk Assessment
Muraglitazar and peliglitazar, two structural analogs differing by a methyl group, are dual peroxisome proliferator-activated receptor-α/γ activators. Both compounds were extensively metabolized in humans through acyl glucuronidation to form 1-O-β-acyl glucuronide (AG) metabolites as the major drug-related components in bile, representing at least 15 to 16% of the dose after oral administration. Peliglitazar AG was the major circulating metabolite, whereas muraglitazar AG was a very minor circulating metabolite in humans. Peliglitazar AG circulated at lower concentrations in animal species than in humans. Both compounds had a similar glucuronidation rate in UDP-glucuronic acid-fortified human liver microsomal incubations and a similar metabolism rate in human hepatocytes. Muraglitazar AG and peliglitazar AG were chemically synthesized and found to be similarly oxidized through hydroxylation and O-demethylation in NADPH-fortified human liver microsomal incubations. Peliglitazar AG had a greater stability than muraglitazar AG in incubations in buffer, rat, or human plasma (pH 7.4). Incubations of muraglitazar AG or peliglitazar AG in plasma produced more aglycon than acyl migration products compared with incubations in the buffer. These data suggested that the difference in plasma stability, not differences in intrinsic formation, direct excretion, or further oxidation of muraglitazar AG or peliglitazar AG, contributed to the observed difference in the circulation of these AG metabolites in humans. The study demonstrated the difficulty in doing risk assessment based on metabolite exposure in plasma because the more reactive muraglitazar AG would not have triggered a threshold of concern based on the recent U.S. Food and Drug Administration guidance on Metabolites in Safety Testing, whereas the more stable peliglitazar AG would have.
- 1 January 2011
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 39 (1) , 123-131
Plasma Stability-Dependent Circulation of Acyl Glucuronide Metabolites in Humans: How Circulating Metabolite Profiles of Muraglitazar and Peliglitazar Can Lead to Misleading Risk Assessment
Muraglitazar and peliglitazar, two structural analogs differing by a methyl group, are dual peroxisome proliferator-activated receptor-α/γ activators. Both compounds were extensively metabolized in humans through acyl glucuronidation to form 1-O-β-acyl glucuronide (AG) metabolites as the major drug-related components in bile, representing at least 15 to 16% of the dose after oral administration. Peliglitazar AG was the major circulating metabolite, whereas muraglitazar AG was a very minor circulating metabolite in humans. Peliglitazar AG circulated at lower concentrations in animal species than in humans. Both compounds had a similar glucuronidation rate in UDP-glucuronic acid-fortified human liver microsomal incubations and a similar metabolism rate in human hepatocytes. Muraglitazar AG and peliglitazar AG were chemically synthesized and found to be similarly oxidized through hydroxylation and O-demethylation in NADPH-fortified human liver microsomal incubations. Peliglitazar AG had a greater stability than muraglitazar AG in incubations in buffer, rat, or human plasma (pH 7.4). Incubations of muraglitazar AG or peliglitazar AG in plasma produced more aglycon than acyl migration products compared with incubations in the buffer. These data suggested that the difference in plasma stability, not differences in intrinsic formation, direct excretion, or further oxidation of muraglitazar AG or peliglitazar AG, contributed to the observed difference in the circulation of these AG metabolites in humans. The study demonstrated the difficulty in doing risk assessment based on metabolite exposure in plasma because the more reactive muraglitazar AG would not have triggered a threshold of concern based on the recent U.S. Food and Drug Administration guidance on Metabolites in Safety Testing, whereas the more stable peliglitazar AG would have.
- 1 April 2002
- Published by American Chemical Society (ACS) in Journal of the American Society for Mass Spectrometry
- Vol. 13 (4) , 345-353
In electrospray ionization source hydrogen/deuterium exchange LC-MS and LC-MS/MS for characterization of metabolites
A new method is described for performing hydrogen/deuterium (H/D) exchange in an electrospray ionization (ESI) source. The use of liquid chromatography (LC)-mass spectrometer equipped with an ESI source and deuterium oxide (D2O) as the sheath liquid allows H/D exchange experiments to be performed on-line. This directly provides information for determining the number and position of exchangeable hydrogens, aiding in the elucidation of the structures of drug metabolites. To demonstrate the utility of this method, LC-mass spectrometry (MS) and LC-MS/MS experiments were performed using either H2O or D2O as sheath liquid on a matrix metalloprotease (MMP) inhibitor (PD 0200126) and its metabolites. Examination of the mass shift of the deuteriated molecule from that of the protonated molecule allowed the number of exchangeable protons to be determined. Interpretation of the production-spectra helped to determine the location of the exchanged protons and assisted in the assignment of the site(s) of modification for each metabolite.
- 1 April 2002
- Published by American Chemical Society (ACS) in Journal of the American Society for Mass Spectrometry
- Vol. 13 (4) , 345-353
In electrospray ionization source hydrogen/deuterium exchange LC-MS and LC-MS/MS for characterization of metabolites
A new method is described for performing hydrogen/deuterium (H/D) exchange in an electrospray ionization (ESI) source. The use of liquid chromatography (LC)-mass spectrometer equipped with an ESI source and deuterium oxide (D2O) as the sheath liquid allows H/D exchange experiments to be performed on-line. This directly provides information for determining the number and position of exchangeable hydrogens, aiding in the elucidation of the structures of drug metabolites. To demonstrate the utility of this method, LC-mass spectrometry (MS) and LC-MS/MS experiments were performed using either H2O or D2O as sheath liquid on a matrix metalloprotease (MMP) inhibitor (PD 0200126) and its metabolites. Examination of the mass shift of the deuteriated molecule from that of the protonated molecule allowed the number of exchangeable protons to be determined. Interpretation of the production-spectra helped to determine the location of the exchanged protons and assisted in the assignment of the site(s) of modification for each metabolite.
- 17 December 2001
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 28 (5) , 945-951
Application of semi-automated metabolite identification software in the drug discovery process for rapid identification of metabolites and the cytochrome P450 enzymes responsible for their formation
- 17 December 2001
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 28 (5) , 945-951
Application of semi-automated metabolite identification software in the drug discovery process for rapid identification of metabolites and the cytochrome P450 enzymes responsible for their formation